摘要
IMPORTANCE: Randomized trials have established anatomical segmentectomy as an acceptable alternative to lobectomy for selected patients with peripheral, node-negative Non Small Cell Lung Cancer (NSCLC) ≤2 cm. However, trial populations were highly selected, and tumour diameter alone does not capture the biological heterogeneity of early-stage disease. OBJECTIVE: To critically review the importance of tumour biology on outcomes following lobectomy or segmentectomy. DESIGN: A structured search of Undermind and PubMed identified comparative studies, randomized trials, meta-analyses, and consensus evidence available through August 10, 2026. Evidence was critically appraised and synthesized narratively, with emphasis on recurrence, survival, staging, and technical quality. RESULTS: Segmentectomy provides excellent outcomes when adequate margins, anatomical completeness, and rigorous nodal assessment are achieved. Ground-glass opacity (GGO)-dominant tumours, particularly those with low consolidation-to-tumour ratio (CTR), represent the strongest candidates for parenchymal preservation. Increasing CTR, pure-solid morphology, larger size, high Fluorodeoxyglucose (FDG) uptake, micropapillary or solid histology, spread through air spaces (STAS), visceral pleural invasion, and lymphovascular invasion identify progressively higher-risk phenotypes, but none alone consistently proves that lobectomy improves survival. Micropapillary components exceeding approximately 5%, STAS, inadequate margins, incomplete staging, and multiple coexisting adverse features strengthen the rationale for lobectomy. Segmentectomy is generally preferable to wedge resection for solid, deeper, or biologically aggressive lesions, whereas wedge resection remains reasonable for carefully selected small, peripheral, GGO-dominant tumours. The favourable results of randomized trials depend on accurate preoperative and intraoperative staging and should not be generalized to unselected cT1c or biologically aggressive tumours. CONCLUSIONS AND RELEVANCE: Sublobar resection should be viewed as refined selection rather than replacement of lobectomy. Tumour size defines eligibility, but biology increasingly determines suitability. Precision surgery will require prospective validation of integrated models combining morphology, metabolism, pathology, molecular biomarkers, patient physiology, and technical quality.